The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term mortality rates among people with advanced cancer, according to results of a cohort study.The analysis included data from 11,797 adults with advanced solid cancers who began first-line treatment during a 1-year interval before the shortage (Feb. 1, 2022, to Feb. 9, 2023) or a
Here is a look back on all the FDA happenings from the month of January 2025.
The adjusted risk for COPD was elevated among adults who identified as regular cigarette smokers before age 15 years, according to results published in Chronic…
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
This issue includes important information on the committee’s initiatives for the upcoming year, including recording podcasts, organizing informal meetups at different society meetings, collaborating with…
The experts in pediatric low-grade gliomas (pLGG) delineate the standard of care for frontline treatment of tumors not harboring the BRAF V600E mutation, outlining current…
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
PHILADELPHIA (January 31, 2025) — Eric Goodlev, MD, an Associate Professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center, was recently named…
Linde Morsink, MD, this year’s recipient of the Editorial Award for Clinical Research, previews her lecture on using post transplantation cyclophosphamide (PTCy) in combination with…
